Vaxart, Inc. (VXRT) shares are trading lower Thursday, a move worth watching in the Healthcare space.The session has seen an intraday range of $0.4500–$0.4899, volume of 443,300 shares.Stripped back, single-session moves of this size often reflect a shift in sentiment or positioning as much as fundamentals.Vaxart shares were down 5.79% at $0.4520 at the time...
Every position is an argument with someone on the other side. Here is what the numbers...
Rather than pick a side, this is the evidence on each. Amtech Systems, Inc. (ASYS) currently...
Here is what actually moved Assembly Biosciences, Inc. (ASMB): the 6 sessions in the last month...
Most sessions tell you nothing. These 6 moved Agenus Inc. (AGEN) enough to be worth explaining...
from H.C. Wainwright issued a price target of $38.00 for BDSX on 2026-09-25 16:29:02.The adjusted price target was set to $38.00.At the time of the announcement, BDSX was trading at...
Jonathan Siegmann from Stifel Nicolaus issued a price target of $6.50 for KOPN on 2026-09-25 13:12:00.The adjusted price target was set to $6.50.At the time of the announcement, KOPN was...
from UBS issued a price target of $2.00 for TELA on 2026-09-25 12:50:21.The adjusted price target was set to $2.00.At the time of the announcement, TELA was trading at $1.275.The...
Erin Wright from Morgan Stanley issued a price target of $1.40 for PETS on 2026-09-25 12:19:32.The adjusted price target was set to $1.40.At the time of the announcement, PETS was...
David Smith from Truist Financial issued a price target of $172.00 for BNY on 2026-09-25 11:41:51.The adjusted price target was set to $172.00.At the time of the announcement, BNY was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
